Real-world experience with vorasidenib in IDH-mutant gliomas: Tolerability, adverse events, and access in patients who did not meet INDIGO trial eligibility criteria.
Year: 2025
Type: article
Study design: Observational Study
Source: Journal of Clinical Oncology
Authors: Huda Alalami, Jeremy David Rudnick, Joanna Wilson, Almar Guevarra, Rebecca Naor, Jethro Lisien Hu
Institution: Cedars-Sinai Medical Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410820374